{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:59:28Z","timestamp":1783544368124,"version":"3.55.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.hoc.2021.05.011","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:36:45Z","timestamp":1630946205000},"page":"973-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Salivary Gland Cancers"],"prefix":"10.1016","volume":"35","author":[{"given":"Vatche","family":"Tchekmedyian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/JOP.18.00039","article-title":"Challenges and Opportunities for Developing New Therapeutics for Salivary Gland Cancers","volume":"14","author":"Ho","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","article-title":"Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland","volume":"11","author":"Seethala","year":"2017","journal-title":"Head Neck Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib3","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1177\/014556131709600319","article-title":"The rising incidence of major salivary gland cancer in the United States","volume":"96","author":"Del Signore","year":"2017","journal-title":"Ear Nose Throat J"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ijc.20740","article-title":"Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database","volume":"114","author":"Carvalho","year":"2005","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2021.05.011_bib5","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing Incidence of Thyroid Cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib6","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.4317\/medoral.20337","article-title":"Incidence and prevalence of salivary gland tumours in Valparaiso, Chile","volume":"20","author":"Araya","year":"2015","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"6","key":"10.1016\/j.hoc.2021.05.011_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0194-5998(99)70323-2","article-title":"Incidence rates of salivary gland tumors: results from a population-based study","volume":"120","author":"Pinkston","year":"1999","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.oraloncology.2007.05.010","article-title":"The range and demographics of salivary gland tumours diagnosed in a UK population","volume":"44","author":"Jones","year":"2008","journal-title":"Oral Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.oooo.2012.04.008","article-title":"Clinicopathologic analysis of 493 cases of salivary gland tumors in a Southern Brazilian population","volume":"114","author":"Fonseca","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0964-1955(95)00001-X","article-title":"Minor salivary gland tumours. A retrospective study of 164 cases in a Brazilian population","volume":"31B","author":"Loyola","year":"1995","journal-title":"Eur J Cancer B Oral Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.oraloncology.2007.01.016","article-title":"Clinical analysis of salivary gland tumor cases in West China in past 50 years","volume":"44","author":"Li","year":"2008","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bjoms.2012.10.002","article-title":"Incidence of salivary gland neoplasms in a defined UK population","volume":"51","author":"Bradley","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib13","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/cncr.32792","article-title":"Distant metastasis of salivary gland cancer: Incidence, management, and outcomes","volume":"126","author":"Mimica","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib14","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2021.05.011_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/1097-0142(19920201)69:3<615::AID-CNCR2820690303>3.0.CO;2-9","article-title":"The indications for elective treatment of the neck in cancer of the major salivary glands","volume":"69","author":"Armstrong","year":"1992","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2021.05.011_bib16","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archotol.129.7.720","article-title":"High Incidence of Lymph Node Metastasis in Major Salivary Gland Cancer","volume":"129","author":"Stennert","year":"2003","journal-title":"Arch Otolaryngol Neck Surg"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ijrobp.2006.10.044","article-title":"Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?","volume":"67","author":"Chen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1754-9485.2010.02202.x","article-title":"Radiotherapy in treatment of carcinoma of the parotid gland, an approach for the medically or technically inoperable patient","volume":"54","author":"Matthiesen","year":"2010","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3904\/kjim.2019.104","article-title":"Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma","volume":"36","author":"Ha","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijrobp.2010.09.042","article-title":"Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy","volume":"82","author":"Schoenfeld","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archoto.2011.158","article-title":"Adjuvant Radiation Therapy for High-Grade and\/or Locally Advanced Major Salivary Gland Tumors","volume":"137","author":"Mahmood","year":"2011","journal-title":"Arch Otolaryngol Neck Surg"},{"issue":"11","key":"10.1016\/j.hoc.2021.05.011_bib22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamaoto.2016.2168","article-title":"Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base","volume":"142","author":"Amini","year":"2016","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"6","key":"10.1016\/j.hoc.2021.05.011_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hed.24172","article-title":"Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients","volume":"38","author":"Tanvetyanon","year":"2016","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.hoc.2021.05.011_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archoto.2009.70","article-title":"Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma","volume":"135","author":"Tanvetyanon","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.hoc.2021.05.011_bib25","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0360-3016(93)90233-L","article-title":"Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council","volume":"27","author":"Laramore","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0360-3016(88)90188-5","article-title":"Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study","volume":"15","author":"Griffin","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2015.12.008","article-title":"Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation","volume":"118","author":"Romesser","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2214\/ajr.123.1.49","article-title":"Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy","volume":"123","author":"Guillamondegui","year":"1975","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"issue":"9","key":"10.1016\/j.hoc.2021.05.011_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0360-3016(83)90259-6","article-title":"Postoperative irradiation in malignant epithelial tumors of the parotid","volume":"9","author":"McNaney","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.hoc.2021.05.011_bib31","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.6004\/jnccn.2020.7593","article-title":"Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma","volume":"18","author":"Chen","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib32","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/lary.26565","article-title":"Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation","volume":"127","author":"Ali","year":"2017","journal-title":"Laryngoscope"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.oraloncology.2015.10.002","article-title":"Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)","volume":"51","author":"Bj\u00f8rndal","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.hoc.2021.05.011_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib35","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1002\/hed.23383","article-title":"Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy","volume":"36","author":"Soper","year":"2014","journal-title":"Head Neck"},{"issue":"11","key":"10.1016\/j.hoc.2021.05.011_bib36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.hoc.2021.05.011_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1159\/000514850","article-title":"Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression","volume":"14","author":"Berendika","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9610(97)00153-0","article-title":"Distant metastasis in adenoid cystic carcinoma of salivary origin","volume":"174","author":"Spiro","year":"1997","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archotol.125.2.149","article-title":"Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality","volume":"125","author":"Fordice","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.hoc.2021.05.011_bib42","doi-asserted-by":"crossref","first-page":"104690","DOI":"10.1016\/j.oraloncology.2020.104690","article-title":"Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma","volume":"106","author":"Hanna","year":"2020","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hed.10126","article-title":"Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up","volume":"24","author":"van der Wal","year":"2002","journal-title":"Head Neck"},{"issue":"44","key":"10.1016\/j.hoc.2021.05.011_bib44","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","article-title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck","volume":"106","author":"Persson","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"10.1016\/j.hoc.2021.05.011_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Ho","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2021.05.011_bib46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/eye.2016.307","article-title":"Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement","volume":"31","author":"Chen","year":"2017","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib47","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/oxfordjournals.annonc.a010770","article-title":"Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group","volume":"7","author":"Verweij","year":"1996","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib49","first-page":"892","article-title":"Vinorelbine treatment of recurrent salivary gland carcinomas","volume":"85","author":"Airoldi","year":"1998","journal-title":"Bull Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2021.05.011_bib50","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S","article-title":"Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients","volume":"68","author":"Licitra","year":"1991","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archotol.1981.00790480015004","article-title":"Cisplatin therapy for adenoid cystic carcinoma","volume":"107","author":"Schramm","year":"1981","journal-title":"Arch Otolaryngol"},{"issue":"9","key":"10.1016\/j.hoc.2021.05.011_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","article-title":"Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib54","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mpo.2950160309","article-title":"Preliminary experience with chemotherapy in advanced salivary gland neoplasms","volume":"16","author":"Belani","year":"1988","journal-title":"Med Pediatr Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2021.05.011_bib56","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2008.08.014","article-title":"Phase II study on gemcitabine in recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)","volume":"44","author":"van Herpen","year":"2008","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.hoc.2021.05.011_bib58","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A\u00a0phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.hoc.2021.05.011_bib60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A\u00a0phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: Translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib61","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A\u00a0phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib63","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1200\/JCO.2016.34.15_suppl.6096","article-title":"Phase II study of regorafenib in progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"34","author":"Ho","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2021.05.011_bib64","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","article-title":"A\u00a0phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"23","author":"Dillon","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2021.05.011_bib65","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib66","first-page":"956","article-title":"KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma","volume":"12","author":"Holst","year":"1999","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A\u00a0phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2021.05.011_bib68","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib69","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hoc.2021.05.011_bib71","article-title":"Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J\u00a0Thyroid Res"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"issue":"18","key":"10.1016\/j.hoc.2021.05.011_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.05.011_bib74","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib75","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl_4","key":"10.1016\/j.hoc.2021.05.011_bib76","first-page":"S599","article-title":"ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","volume":"31","author":"Ferrarotto","year":"2020","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2021.05.011_bib77","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A\u00a0phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib78","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A\u00a0Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib79","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib80","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1200\/JCO.2019.37.15_suppl.6084","article-title":"A\u00a0phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC)","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib81","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20180939","article-title":"Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma","volume":"215","author":"Mandelbaum","year":"2018","journal-title":"J\u00a0Exp Med"},{"issue":"Supplement 5","key":"10.1016\/j.hoc.2021.05.011_bib82","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumors","volume":"30","author":"Siu","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib83","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","article-title":"Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis","volume":"44","author":"Klein Nulent","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib84","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.7150\/thno.38501","article-title":"(68)Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study","volume":"10","author":"van Boxtel","year":"2020","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.hoc.2021.05.011_bib85","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0030-4220(94)90119-8","article-title":"Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature","volume":"78","author":"Barnes","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib87","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/cncr.21116","article-title":"Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases","volume":"103","author":"Jaehne","year":"2005","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2021.05.011_bib88","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib89","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1200\/JCO.2016.34.15_suppl.6016","article-title":"Salivary duct carcinoma: Clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease (n=31)\u2014Study of the Dutch head and neck society (DHNS)","volume":"34","author":"Boon","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib90","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A\u00a0prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib91","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1200\/JCO.2019.37.15_suppl.6020","article-title":"Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers","volume":"37","author":"Ho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.05.011_bib92","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib94","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab","volume":"11","author":"Corr\u00eaa","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.05.011_bib96","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib97","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen Receptor Signaling in Salivary Gland Cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.hoc.2021.05.011_bib99","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-15-2568","article-title":"Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.05.011_bib100","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3389\/fonc.2020.580141","article-title":"Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease","volume":"10","author":"Di Villeneuve","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib101","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/lary.24254","article-title":"Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy","volume":"124","author":"Sethi","year":"2014","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib104","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib106","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib107","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ng1083","article-title":"t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway","volume":"33","author":"Tonon","year":"2003","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.hoc.2021.05.011_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139497","article-title":"The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.hoc.2021.05.011_bib109","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.oraloncology.2017.02.025","article-title":"Correlation of Crtc1\/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma","volume":"68","author":"Birkeland","year":"2017","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.05.011_bib110","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/PAS.0b013e3181de3021","article-title":"A\u00a0reappraisal of the MECT1\/MAML2 translocation in salivary mucoepidermoid carcinomas","volume":"34","author":"Seethala","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib111","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoto.2015.3270","article-title":"Role of CRTC1\/MAML2 Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid Carcinoma","volume":"142","author":"Saade","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.hoc.2021.05.011_bib112","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12885-015-1827-3","article-title":"Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib113","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/modpathol.2009.126","article-title":"Clinicopathological significance of the CRTC3\u2013MAML2 fusion transcript in mucoepidermoid carcinoma","volume":"22","author":"Nakayama","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2021.05.011_bib114","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hed.23256","article-title":"Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients","volume":"36","author":"Chen","year":"2014","journal-title":"Head Neck"},{"issue":"29","key":"10.1016\/j.hoc.2021.05.011_bib115","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/onc.2013.348","article-title":"Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.hoc.2021.05.011_bib116","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/JTO.0b013e318237746a","article-title":"Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma","volume":"6","author":"Lee","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib117","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lungcan.2008.09.007","article-title":"Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis","volume":"63","author":"Rossi","year":"2009","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2007.11.014","article-title":"Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment","volume":"61","author":"Han","year":"2008","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2021.05.011_bib119","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.hoc.2021.05.011_bib120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/annonc\/mdw689","article-title":"Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations","volume":"28","author":"Wang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.05.011_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1097-0347(199907)21:4<297::AID-HED2>3.0.CO;2-R","article-title":"National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma","volume":"21","author":"Hoffman","year":"1999","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.hoc.2021.05.011_bib122","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/1097-0142(197803)41:3<924::AID-CNCR2820410321>3.0.CO;2-L","article-title":"Acinic cell carcinoma of salivary origin. A clinicopathologic study of 67 cases","volume":"41","author":"Spiro","year":"1978","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2021.05.011_bib123","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-2007-998664","article-title":"[Acinar cell carcinoma of the salivary glands]","volume":"66","author":"Zb\u00e4ren","year":"1987","journal-title":"Laryngol Rhinol Otol (Stuttg)"},{"issue":"1","key":"10.1016\/j.hoc.2021.05.011_bib124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-018-08069-x","article-title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands","volume":"10","author":"Haller","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2021.05.011_bib125","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the Phase 1b KEYNOTE-028 Study","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib126","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2021.05.011_bib127","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:29Z","timestamp":1760184929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0889858821000770"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.05.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salivary Gland Cancers","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}